Wu Y.-L.,Guangdong General Hospital and Guangdong Academy of Medical science |
Lu S.,Shanghai JiaoTong University |
Cheng Y.,Cancer Hospital of Jilin Province |
Zhou C.,Tongji University |
And 11 more authors.
Lung Cancer | Year: 2014
Objectives: Retrospective subgroup analysis in JMDB study indicates that the between-arm differences in overall survival (OS) in the East Asian subgroup were consistent with those observed in the entire JMDB study population. This bridging study (JMIL) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin (PC) versus gemcitabine/cisplatin (GC) in Chinese patients with nonsquamous non-small cell lung cancer (NSCLC). The primary endpoint of this local registration trial was designed to compare OS in the combined dataset, consisting of Chinese patients in JMIL and 1252 nonsquamous patients in JMDB. Materials and methods: Chinese patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned (1:1) to 6 cycles maximum (21 days/cycle) of pemetrexed 500mg/m2+cisplatin 75mg/m2 (day 1), or gemcitabine 1250mg/m2 (days 1 and 8)+cisplatin 75mg/m2 (day 1). Results: In JMIL, 256 Chinese patients were randomized (PC, n = 126; GC, n = 130). Patient baseline characteristics were balanced between treatment arms. In the combined dataset, PC was superior to GC in prolonging OS, with adjusted hazard ratio (HR) of 0.87 (95% CI: 0.77-0.98, p = 0.023) and median OS of 11.76 versus 10.94 months. In the JMIL-only population, no significant OS difference observed between treatment arms (adjusted HR. = 1.03 [95% CI: 0.77-1.39, p = 0.822]; unadjusted HR. = 0.996 [95% CI: 0.74-1.33, p = 0.980]), nor for other secondary efficacy endpoints. Significantly fewer patients in the PC arm experienced drug-related grade 3/4 toxicities, 54 (43.2%) versus 71 (55.9%) for GC (p = 0.045), with significantly lower rates of leukocytopenia, thrombocytopenia, and fatigue. Conclusion: This study showed that in the combined population, OS of PC was superior to GC, while in the Chinese-only population, no significant difference was observed; a better safety and risk/benefit profile was found in the PC arm. A PC regimen should be considered as a standard of care in Chinese nonsquamous NSCLC patients in a first-line setting. © 2014 Elsevier Ireland Ltd.
Yang Y.-J.,Cancer Hospital of Jilin Province |
Cao L.,Cancer Hospital of Jilin Province |
Li Z.-W.,Jilin University |
Zhao L.,Cancer Hospital of Jilin Province |
And 5 more authors.
Oncotarget | Year: 2016
To measure the safety and efficacy of oxaliplatin (OX) application in neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC), EMBASE, PubMed, Cochrane Library, and Web of Science were used for a literature search. Cochrane's risk of bias tool of randomized controlled trials (RCTs) was used for quality evaluation. The statistical analyses were performed using RevMan 5.3. In addition, 95% confidence intervals (CIs) and pooled risk ratios (RRs) were calculated. Seven RCTs were included in our meta-analysis. After adding OX to fluoropyrimidine (FU), a marginal significant improvement in disease-free survival was noted compared with FU alone (RR = 0.89, 95% CI: 0.78-1.00; P = 0.05). Neoadjuvant CRT with OX significantly decreased the distant metastasis rate (RR = 0.79, 95% CI: 0.67-0.94, P = 0.007). However, no improvement in the local recurrence rate (RR = 0.86, 95% CI: 0.68-1.08; P = 0.19) was noted. In addition, neoadjuvant CRT with OX also significantly increased the pathologic complete response (RR = 1.24, 95% CI: 1.02-1.51; P = 0.03). Grade 3-4 acute toxicity and grade 3-4 diarrhea was considerably higher for OX/FU compared with FU alone. In conclusion, the use of OX on the basis of FU/ capecitabine in preoperative CRT is feasible. LARC patients are likely to benefit from CRT regimens with OX.
Zhang P.,Jilin University |
He Y.,Jilin University |
Liu J.,Jilin University |
Feng J.,CAS Changchun Institute of Applied Chemistry |
And 4 more authors.
RSC Advances | Year: 2016
Lanthanide-doped nanocrystals have been researched extensively and used for bioimaging because of their optical properties, magnetic properties and X-ray absorption. Core-shell-structured lanthanide-doped nanocrystals have been developed and characterized by TEM and XRD analysis. The nanocrystals are composed of BaYbF5:0.5% Tm as the core and BaGdF5:20% Yb, 0.5% Tm as the shell. Apart from characterization of the nanocrystals, evaluation of both their cytotoxicity via MTT assays and their long-term toxicity via histological analysis showed that their cytotoxicity was low, indicating the possibility of further in vivo imaging. This work combined the functions of trimodal imaging into one nanoplatform and then UCL, CT, and MR imaging with core-shell-structured nanocrystals were investigated both in vitro and in vivo. Taking into consideration its structural characteristics and trimodal imaging abilities, it is expected that the developed multifunctional nanoplatform may be potentially useful for diagnosing diseases at an early stage. © 2016 The Royal Society of Chemistry.
Sun Y.,Cancer Hospital of Jilin Province |
Du Y.-J.,Jilin University |
Zhao H.,Cancer Hospital of Jilin Province |
Zhang G.-X.,Cancer Hospital of Jilin Province |
And 2 more authors.
Journal of Radiation Research | Year: 2016
The effectiveness of ulinastatin and methylprednisolone in treating pathological changes in mice with radiation-induced lung injury (RILI) was evaluated. Forty C57BL/6 female mice received whole-chest radiation (1.5 Gy/min for 12 min) and were randomly allocated into Group R (single radiation, n = 10), Group U (ulinastatin treatment, n = 10), Group M (methylprednisolone treatment, n = 10), or Group UM (ulinastatin and methylprednisolone treatment, n = 10). Another 10 untreated mice served as controls (Group C). Pathological changes in lung tissue, pulmonary interstitial area density (PIAD) and expression levels of transforming growth factor β1 (TGF-β1) and tumor necrosis factor α (TNF-α) in lung tissue, serum and bronchoalveolar lavage fluid were determined. Alleviation of pathological changes in lung tissue was observed in Groups U, M and UM. Treatment with ulinastatin, methylprednisolone or both effectively delayed the development of fibrosis at 12 weeks after radiation. Ulinastatin, methylprednisolone or both could alleviate the radiation-induced increase in the PIAD (P < 0.05 or P < 0.01). Treatment with ulinastatin, methylprednisolone or both significantly reduced the expression of TNF-α, but not TGF-β1, at 9 weeks after radiation compared with Group R (P < 0.01). Ulinastatin and/or methylprednisolone effectively decreased the level of TNF-α in lung tissue after RILI and inhibited both the inflammatory response and the development of fibrosis. © 2016 The Author 2016. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology.
Liu X.,Jilin University |
Yan S.,Cancer Hospital of Jilin Province |
Pei C.,Jilin Province Peoples Hospital |
Cui Y.,Jilin University
Molecular Medicine Reports | Year: 2015
MicroRNA-132 (miR-132) has been shown to be dysregulated in certain types of human malignancies and is associated with tumor progression. However, its function in non-small cell lung cancer (NSCLC) and whether it is differentially expressed in this disease, remain unclear. Thus, the aim of the present study was to investigate the effects of miR-132 on NSCLC tumorigenesis and progression. Using reverse transcription-quantitative polymerase chain reaction, miR-132 expression was detected in NSCLC cell lines and primary tumor tissues. The association between miR-132 expression, and clinicopathological factors and prognosis was assessed using statistical analysis. An MTT assay, flow cytometry, Transwell invasion assays and scratch migration assays were conducted in order to examine the proliferation, apoptosis, invasion and migration of NSCLC cells that had been transfected with miR-132 mimics or inhibitors. The results showed that miR-132 expression levels were significantly downregulated in NSCLC cells compared with that in corresponding non-cancerous lung tissues (P<0.001). In addition, reduced miR-132 expression was significantly associated with lymph node metastasis (P=0.003), an advanced tumor-node-metastasis stage (P<0.001) and shorter overall survival (P<0.001). Multivariate regression analysis confirmed that downregulation of miR-132 was an independent predictor of prognosis. Furthermore, transfection of miR-132 mimics into the NSCLC cells reduced cell proliferation, invasion and migration, and promoted cell apoptosis. These findings indicate that miR-132 may be a novel diagnostic and prognostic marker, as well as a potential target for molecular therapy in NSCLC.
Ding Y.,Jilin University |
Zhang H.,Jilin University |
Li Y.,Jilin University |
Wu D.,Cancer Hospital of Jilin Province |
And 4 more authors.
International Journal of Medical Sciences | Year: 2013
siRNA (small interfering RNA) interference represents an exciting new technology that could have therapeutic applications for the treatment of viral infections. However, a major challenge in the use of siRNA as a therapeutic agent is the development of a suitable delivery system. We demonstrated that a new non-viral transgene carrier, recombinant archaeal histone from the hyperthermophile Pyrococcus horikoshii OT3 (HPhA), can transfect short hairpin RNA (shRNA) expressing plasmids into HL-7702 cells to inhibit the expression of HCV 5'NTR and Core protein and mRNA. Plasmids Psilencirle transfected by HPhA inhibited the expression of HCV 5'-NTR and Core protein and mRNA in HL-7702 cells. The transfection efficiency of HPhA in HL-7702 cells was not affected by 10% fetal calf serum (FCS). HPhA exhibited effects of transfection without apparent toxicity, and with high affinity for DNA. This suggests that HPhA may be useful for RNAi-based gene therapy in vivo. © Ivyspring International Publisher.
PubMed | Jilin University, Fudan University and Cancer Hospital of Jilin Province
Type: Journal Article | Journal: Oncotarget | Year: 2016
To measure the safety and efficacy of oxaliplatin (OX) application in neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC), EMBASE, PubMed, Cochrane Library, and Web of Science were used for a literature search. Cochranes risk of bias tool of randomized controlled trials (RCTs) was used for quality evaluation. The statistical analyses were performed using RevMan 5.3. In addition, 95% confidence intervals (CIs) and pooled risk ratios (RRs) were calculated. Seven RCTs were included in our meta-analysis. After adding OX to fluoropyrimidine (FU), a marginal significant improvement in disease-free survival was noted compared with FU alone (RR = 0.89, 95% CI: 0.78-1.00; P = 0.05). Neoadjuvant CRT with OX significantly decreased the distant metastasis rate (RR = 0.79, 95% CI: 0.67-0.94, P = 0.007). However, no improvement in the local recurrence rate (RR = 0.86, 95% CI: 0.68-1.08; P = 0.19) was noted. In addition, neoadjuvant CRT with OX also significantly increased the pathologic complete response (RR = 1.24, 95% CI: 1.02-1.51; P = 0.03). Grade 3-4 acute toxicity and grade 3-4 diarrhea was considerably higher for OX/FU compared with FU alone. In conclusion, the use of OX on the basis of FU/capecitabine in preoperative CRT is feasible. LARC patients are likely to benefit from CRT regimens with OX.
Wang Z.,CAS Changchun Institute of Applied Chemistry |
Wang Z.,University of Chinese Academy of Sciences |
Feng J.,CAS Changchun Institute of Applied Chemistry |
Song S.,CAS Changchun Institute of Applied Chemistry |
And 6 more authors.
Journal of Materials Chemistry C | Year: 2014
The pure and intense orange upconversion luminescence of Eu3+ was efficiently achieved in NaYF4 and NaLuF4 nanocrystals through the upconversion sensitization of doped Yb3+ and Mn2+ ions dimer for the first time. A shell-coating strategy was performed to further enhance the emission intensity. In this work, a novel upconversion mechanism for energy transfer from the Yb3+-Mn2+ dimer to the Eu3+ ion was proposed by analyzing the upconversion luminescence spectra, lifetimes and pumping photons measurements of the obtained nanocrystals in detail. The applications of the nanocrystals for CT imaging and ratiometric pH sensing in physiological pH range were performed. This study also provides a new upconversion spectral region at around 592 nm for applications in multicolor imaging, multiplexed encoding and detection. © The Royal Society of Chemistry 2014.
Li Z.,Cancer Hospital of Jilin Province |
Liu X.-W.,Cancer Hospital of Jilin Province |
Chi Z.-C.,Cancer Hospital of Jilin Province |
Sun B.-S.,Cancer Hospital of Jilin Province |
And 2 more authors.
PLoS ONE | Year: 2015
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors are useful in treating different advanced human cancers; however, their clinical efficacy varies. This study detected K-ras mutations to predict the efficacy of EGFR-TK inhibitor cetuximab treatment on Chinese patients with metastatic colorectal cancer (mCRC). A total of 87 patients with metastatic colorectal cancer were treated with cetuximab for 2-16 months, in combination with chemotherapy between August 2008 and July 2012, and tissue samples were used to detect K-ras mutations. The data showed that K-ras mutation occurred in 27/87 (31%). The objective response rates and disease control rate in K-ras wild type and mutant patients were 42% (25/60) versus 11% (3/27) (p<0.05) and 60% (36/60) versus 26% (7/27) (p <0.05), respectively. Patients with the wild-type K-ras had significantly higher median survival times and progression-free survival, than patients with mutated K-ras (21 months versus 17 months, p=0.017; 10 months versus 6 months, p=0.6). These findings suggest that a high frequency of K-ras mutations occurs in Chinese mCRC patients and that K-ras mutation is required to select patients for eligibility for cetuximab therapy. Further prospective studies using a large sample size are needed to confirm these preliminary findings. © 2015 Li et al.